OPNT News and Press, Opiant Pharmaceuticals Inc. From 07/07/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Let’s get right into it today with a quick dive into the biggest pre-market stock movers for Wednesday. Source: ventdusud / Shutterstock.com Also, investors wanting to catch up on yester...

Opiant Pharmaceuticals (OPNT) announces positive top-line results from its confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for opioid overdose.Shares up more than 13% post market.The data showed that nasal nalmefene achieved "significantly ...

Data demonstrate rapid absorption and higher plasma concentrations versus an intramuscular injection (p<0.0001) Results confirm findings of initial pilot PK study SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“...

SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, wi...

SANTA MONICA, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that, due to the continuing public health concerns...

Opiant Pharmaceuticals, Inc. (OPNT) Q1 2021 Results Conference Call May 11, 2021 04:30 PM ET Company Participants Ben Atkins - Vice President of Communications and Investor Relations Roger Crystal - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants B...

Opiant Pharmaceuticals (OPNT): Q1 GAAP EPS of -$0.66 beats by $0.09.Revenue of $6.39M (+49.3% Y/Y) beats by $0.7M.Press Release For further details see: Opiant Pharmaceuticals EPS beats by $0.09, beats on revenue

SANTA MONICA, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March ...

SANTA MONICA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the first...

Opiant Pharmaceuticals (OPNT) announces that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with nasal naloxone.The single-center, randomized, open-label study in heathy volunte...